Goldman-Rakic PS (1999) The physiological approach: Functional architecture of working memory and disordered cognition in schizophrenia. Biol Psychiatry 46: 650–661. 8. Durham J (2009). Schizophrenia: A review of pharmacologic and nonpharmacologic treatments.
Psychiatric Rehabilitation Journal, 26 (4), 396. Lysaker, P.H., Wickett, A.M., Wilke, N. & Lysaker, J., (2003). Narrative incoherence in schizophrenia: The absent agent-protagonist and the collapse of internal dialogue. American Journal of Psychotherapy, 57 (2), 153 Marder, S.R., (2000). Integrating pharmacological and psychosocial treatments for schizophrenia.
"Understanding the Causes of Schizophrenia." Editorial. The New England Journal of Medicine 340.8 (1999): 645-47.
Bradford, Daniel W. (1999). “Atypical anti psychotic drugs in treatment refractory schizophrenia”. Psychiatric Annals.
Biological Dysfunction as a Cause for Schizophrenia Schizophrenia is a mental disorder, which is characterised by a number of both positive and negative symptoms. Positive symptoms are behaviours which are present although should be absent. Examples of these are thought disorders resulting in difficulty in arranging thoughts logically, jumping from one topic of conversation to another and speaking random words. Other positive symptoms of schizophrenia include delusions whereby the effected person may feel that people are plotting against them and trying to kill them as well as hallucinations whereby the schizophrenic person hears voices in their head telling them to do things. Negative symptoms are also shown by people suffering from schizophrenia and are the absence of behaviours, which are normally present.
(2002). Psychological treatments in schizophrenia: I. Meta-analysis of family interventions and cognitive behaviour therapy. Psychological Medicine, 32, 763–782. Sensky T., Turkington D., Kingdon D., Scott J. L., Scott J., Siddle R., O'Carroll M. & Barnes T. (2000). A randomised controlled trial of cognitive-behavioural therapy for persistent symptoms in schizophrenia resistant to medication.
Hamilton, M. Fish?s Clinical Psvchopathology, ed. 2, Wright, Bristol, 1985. Henn, F. A., Naerallah, H. A,, editors: Schizophrenia as a Brain Disease. Oxford, New York, 1982. Naerallah, H. A., Weinberger, D. R. The Neurology of Schizophrenia, In Handbook of Schizophrenia, H. A. Nasrallah, editor, Vol.
7. van Megen, H., den Boer J.& Westenberg H. (1994). On the significance of cholecystokinin receptors in panic disorder. Progress in Neuropharnacology and Biological Psychiatry, 18, 1235-1246. 8. van Megen H., Westenberg H., den Boer J., Slaap B.& Scheepmakers A. (1997).
32-42. Sharma, Rajiv P. (1999). Hallucinations in the acute schizophrenic-type psychosis: Effects of gender and age of illness onset. Schizophrenia Research. Vol.
Young, L., Warsh, J. J., Kish, S. J., Shannak, K., & Hornykeiwicz, O. (1994). Reduced Brain 5-HT And Elevated NE Turnover And Metabolites In Bipolar Affective Disorder. Biological Psychiatry, 35(2), 121-127.